Trial Profile
A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Remtolumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 24 Sep 2016 The trial has been completed in Germany (end date: 2016-08-02).
- 16 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 08 Jun 2016 This trial is discontinued in Czech Republic (end ate:2016-07-27) as per European Clinical Trials Database record.